iloprost and Burns

The aim of our study was to demonstrate the decrease in amputation rates with iloprost treatment in patients who develop vascular injury due to burns. The data of 366 adult burn patients who were admitted to the emergency department of our hospital between 2016 and 2019 were analyzed. Demographic characteristics, burn factors, vascular examination findings, medical treatments, amputation rates, and levels were recorded. The amputation rates of the patients who were treated with iloprost and who were not treated with iloprost were compared. The mean age of 366 adult patients treated for burns was 37.8 ± 16.4 years, and of these patients, 220 (59.9%) were under 40 years of age. Although heat burns (n = 331.85%) were the most common burn etiology, it was found that the incidence of vascular injury was higher in burns caused by electricity (11.7%) and cold (3.3%) (P < 0.001). Vascular injury was detected in 60 (16.3%) of the patients and 21 (35%) of these patients were treated with iloprost. Amputation was observed in 20 (5.5%) of all burn patients, but only one of the patients treated with iloprost underwent amputation (P < .001). The individual and social impacts of amputations caused by burns are unquestionable. The authors are of the opinion that iloprost treatment is effective in reducing amputations due to burns.

Topics: Adult; Amputation, Surgical; Burns; Female; Humans; Iloprost; Male; Middle Aged; Vasodilator Agents

Topics: Adult; Arm Injuries; Biopsy, Needle; Burns; Chronic Disease; Clindamycin; Delayed Diagnosis; Drug Therapy, Combination; Follow-Up Studies; Granuloma; Humans; Iloprost; Immunohistochemistry; Injury Severity Score; Male; Risk Assessment; Severity of Illness Index; Skin Ulcer; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome

Topics: Animals; Burns; Epoprostenol; Iloprost; Mice